Page last updated: 2024-12-10

l 779976

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

L 779976: a somatostatin 2 receptor agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

L-779976 : A member of the class of indoles that is (betaS)-beta-methyl-D-tryptophan in which the primary amino group undergoes formal condensation with the carboxy group of 4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidine-1-carboxylic acid and the carboxy group undegoes formal condensation with the amino group of (1R,3S)-cyclohexane-1,3-diyldimethanamine. It is a selective nonpeptidic agonist of the somatostatin subtype-2 (SST2) receptor with Ki of 0.05 nM. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9873146
CHEBI ID176977
MeSH IDM0336548

Synonyms (16)

Synonym
(betas)-n-{[(1r,3s)-3-(aminomethyl)cyclohexyl]methyl}-beta-methyl-nalpha-{[4-(2-oxo-2,3-dihydro-1h-benzimidazol-1-yl)piperidin-1-yl]carbonyl}-d-tryptophanamide
214770-19-1
l-779976
n-[(2r,3s)-1-({[(1r,3s)-3-(aminomethyl)cyclohexyl]methyl}amino)-3-(1h-indol-3-yl)-1-oxobutan-2-yl]-4-(2-oxo-2,3-dihydro-1h-benzimidazol-1-yl)piperidine-1-carboxamide
CHEBI:176977
PDSP2_001425
l779976
l 779976
l 779,976
u5b58a46qx ,
unii-u5b58a46qx
n-((2r,3s)-1-((((1r,3s)-3-(aminomethyl)cyclohexyl)methyl)amino)-3-(1h-indol-3-yl)-1-oxobutan-2-yl)-4-(2-oxo-2,3-dihydro-1h-benzo[d]imidazol-1-yl)piperidine-1-carboxamide
n-[(2r,3s)-1-[[(1r,3s)-3-(aminomethyl)cyclohexyl]methylamino]-3-(1h-indol-3-yl)-1-oxobutan-2-yl]-4-(2-oxo-3h-benzimidazol-1-yl)piperidine-1-carboxamide
1h-indole-3-propanamide, n-(((1r,3s)-3-(aminomethyl)cyclohexyl)methyl)-.alpha.-(((4-(2,3-dihydro-2-oxo-1h-benzimidazol-1-yl)-1-piperidinyl)carbonyl)amino)-.beta.-methyl-, (.alpha.r,.beta.s)-
(.alpha.r,.beta.s)-n-(((1r,3s)-3-(aminomethyl)cyclohexyl)methyl)-.alpha.-(((4-(2,3-dihydro-2-oxo-1h-benzimidazol-1-yl)-1-piperidinyl)carbonyl)amino)-.beta.-methyl-1h-indole-3-propanamide
AKOS040748710
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
somatostatin receptor agonistAn agonist that binds to and activates somatostatin receptors.
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
primary amino compoundA compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
indolesAny compound containing an indole skeleton.
benzimidazolesAn organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
piperidinecarboxamide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (4.17)18.2507
2000's20 (83.33)29.6817
2010's3 (12.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]